These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 22213593)

  • 21. Process induced disorder in crystalline materials: differentiating defective crystals from the amorphous form of griseofulvin.
    Feng T; Pinal R; Carvajal MT
    J Pharm Sci; 2008 Aug; 97(8):3207-21. PubMed ID: 17990307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular dynamics simulation of amorphous indomethacin.
    Xiang TX; Anderson BD
    Mol Pharm; 2013 Jan; 10(1):102-14. PubMed ID: 23116319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Microcosmic mechanisms of amorphous indomethacin crystallization and the influence of nano-coating on crystallization].
    Hui OY; Yi T; Zheng Q; Liu F
    Yao Xue Xue Bao; 2011 Jun; 46(6):707-12. PubMed ID: 21882533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigation of properties and recrystallisation behaviour of amorphous indomethacin samples prepared by different methods.
    Karmwar P; Graeser K; Gordon KC; Strachan CJ; Rades T
    Int J Pharm; 2011 Sep; 417(1-2):94-100. PubMed ID: 21182910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of counterion on the phase behaviour during lyophilization of indomethacin salt forms.
    Kumar L; Baheti A; Mokashi A; Bansal AK
    Eur J Pharm Sci; 2011 Sep; 44(1-2):136-41. PubMed ID: 21767640
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The influence of thermal and mechanical preparative techniques on the amorphous state of four poorly soluble compounds.
    Patterson JE; James MB; Forster AH; Lancaster RW; Butler JM; Rades T
    J Pharm Sci; 2005 Sep; 94(9):1998-2012. PubMed ID: 16052554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Wet milling induced physical and chemical instabilities of naproxen nano-crystalline suspensions.
    Kumar S; Burgess DJ
    Int J Pharm; 2014 May; 466(1-2):223-32. PubMed ID: 24614581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved physical stability of amorphous state through acid base interactions.
    Telang C; Mujumdar S; Mathew M
    J Pharm Sci; 2009 Jun; 98(6):2149-59. PubMed ID: 18837038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In situ amorphisation of indomethacin with Eudragit® E during dissolution.
    Priemel PA; Laitinen R; Grohganz H; Rades T; Strachan CJ
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1259-65. PubMed ID: 24056054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stabilization of amorphous indomethacin by co-grinding in a ternary mixture.
    Watanabe T; Ohno I; Wakiyama N; Kusai A; Senna M
    Int J Pharm; 2002 Jul; 241(1):103-11. PubMed ID: 12086726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Using the low-frequency Raman spectroscopy to analyze the crystallization of amorphous indomethacin.
    Hédoux A; Paccou L; Guinet Y; Willart JF; Descamps M
    Eur J Pharm Sci; 2009 Sep; 38(2):156-64. PubMed ID: 19591926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of milling conditions on the solid-state conversion of ranitidine hydrochloride form 1.
    Chieng N; Zujovic Z; Bowmaker G; Rades T; Saville D
    Int J Pharm; 2006 Dec; 327(1-2):36-44. PubMed ID: 16949221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. X-ray powder diffractometry in combination with principal component analysis--a tool for monitoring solid state changes.
    Kogermann K; Veski P; Rantanen J; Naelapää K
    Eur J Pharm Sci; 2011 Jul; 43(4):278-89. PubMed ID: 21575718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamics of the amorphous and crystalline alpha-, gamma-phases of indomethacin.
    Carpentier L; Decressain R; Desprez S; Descamps M
    J Phys Chem B; 2006 Jan; 110(1):457-64. PubMed ID: 16471556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of different preparation methods on the dissolution behaviour of amorphous indomethacin.
    Karmwar P; Graeser K; Gordon KC; Strachan CJ; Rades T
    Eur J Pharm Biopharm; 2012 Feb; 80(2):459-64. PubMed ID: 22019529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Crystallization pathways and kinetics of carbamazepine-nicotinamide cocrystals from the amorphous state by in situ thermomicroscopy, spectroscopy, and calorimetry studies.
    Seefeldt K; Miller J; Alvarez-Núñez F; Rodríguez-Hornedo N
    J Pharm Sci; 2007 May; 96(5):1147-58. PubMed ID: 17455346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stabilization of low glass transition temperature indomethacin formulations: impact of polymer-type and its concentration.
    Chokshi RJ; Shah NH; Sandhu HK; Malick AW; Zia H
    J Pharm Sci; 2008 Jun; 97(6):2286-98. PubMed ID: 17879977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Indomethacin: new polymorphs of an old drug.
    Surwase SA; Boetker JP; Saville D; Boyd BJ; Gordon KC; Peltonen L; Strachan CJ
    Mol Pharm; 2013 Dec; 10(12):4472-80. PubMed ID: 24025118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigation of griseofulvin and hydroxypropylmethyl cellulose acetate succinate miscibility in ball milled solid dispersions.
    Al-Obaidi H; Lawrence MJ; Al-Saden N; Ke P
    Int J Pharm; 2013 Feb; 443(1-2):95-102. PubMed ID: 23299082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Features of heat-induced amorphous complex between indomethacin and lidocaine.
    Shimada Y; Goto S; Uchiro H; Hirabayashi H; Yamaguchi K; Hirota K; Terada H
    Colloids Surf B Biointerfaces; 2013 Feb; 102():590-6. PubMed ID: 23104030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.